PepGen Inc. (PEPG) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PepGen Inc. is running a Phase 1 trial called FREEDOM-DM1 to test PGN-EDODM1 in adults with myotonic dystrophy type 1. The main aim is to check safety and how the drug moves and acts in the body, which is an early but important step toward a possible new treatment option.
The study tests a single dose of PGN-EDODM1, given by intravenous infusion. It is compared with a placebo saline infusion to see how patients respond and to spot any safety signals tied directly to the drug.
The trial is interventional and randomized, with patients placed into either the drug or placebo arm. It uses a double blind style where participants, doctors, and assessors do not know who gets what, and the main goal is treatment focused, not just observation.
The study started after first submission on 5 December 2023 and is now listed as completed, marking a key early milestone for PepGen’s DM1 program. The latest update was filed on 12 February 2026, signaling fresh information and likely internal review of safety and early response data.
For investors, a completed Phase 1 safety study can reduce some development risk and may support sentiment toward PEPG if data are clean. The update also matters in the wider genetic medicine space, where investors watch how smaller players position against larger neuromuscular names and broader RNA and oligo pipelines.
The study has been completed and recently updated, with further details available on the ClinicalTrials portal.
To learn more about PEPG’s potential, visit the PepGen Inc. drug pipeline page.